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Abstract
Background: Basal cell carcinoma (BCC) is the most common cancer in Caucasians. Trichoepithelioma (TE) is a benign
neoplasm that strongly resembles BCC. Both are hair follicle (HF) tumours. HFs are hypoxic microenvironments, therefore we
hypothesized that hypoxia-induced signalling pathways could be involved in BCC and TE as they are in other human
malignancies. Hypoxia-inducible factor 1 (HIF1) and mechanistic/mammalian target of rapamycin (mTOR) are key players in
these pathways.
Objectives: To determine whether HIF1/mTOR signalling is involved in BCC and TE.
Methods:We used immunohistochemical staining of formalin-fixed paraffin-embedded BCC (n= 45) and TE (n= 35) samples
to assess activity of HIF1, mTORC1 and their most important target genes. The percentage positive tumour cells was
assessed manually in a semi-quantitative manner and categorized (0%, ,30%, 30–80% and .80%).
Results: Among 45 BCC and 35 TE examined, expression levels were respectively 81% and 57% (BNIP3), 73% and 75%
(CAIX), 79% and 86% (GLUT1), 50% and 19% (HIF1a), 89% and 88% (pAKT), 55% and 61% (pS6), 15% and 25% (pMTOR), 44%
and 63% (PHD2) and 44% and 49% (VEGF-A). CAIX, Glut1 and PHD2 expression levels were significantly higher in TE when
only samples with at least 80% expression were included.
Conclusions: HIF and mTORC1 signalling seems active in both BCC and TE. There are no appreciable differences between
the two with respect to pathway activity. At this moment immunohistochemical analyses of HIF, mTORC1 and their target
genes does not provide a reliable diagnostic tool for the discrimination of BCC and TE.
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Introduction
Basal cell carcinoma (BCC) is the most common cancer in
Caucasians. Its incidence is increasing by 3–10% annually, leading
to a lifetime BCC risk in Caucasians of approximately 1 in 5–6. [1]
Sun-exposed body sites like the head and neck are most commonly
affected. [1] Histologically, BCC can be classified into three main
subtypes: superficial, nodular and infiltrative. [2] Youssef et al.
were the first to show that BCC are epithelial tumours originating
from progenitor cells of the interfollicular epidermis (IFE) and the
upper infundibulum. [3] Later evidence shows that BCC can also
arise from the hair follicle (HF) bulge. [4] Trichoepithelioma (TE)
is a similar, though benign epithelial tumour which expresses
markers that are also present in the outer root sheath of the HF
[5,6], which suggests that TE originate from the HF as well. Two
distinct subtypes of TE are recognized: the classic and the
desmoplastic type. [6] Some TE can mimic BCC macroscopically,
[6] making it difficult to differentiate between both tumours and
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this dilemma can extend to the microscopic level. Histologically,
both BCC and TE are characterised by dermal nests of basaloid
cells. TE differs from BCC by its absence of peripheral palisading
of basaloid keratinocytes, necrosis, retraction artefact, mitotic
activity and peritumoral mucin deposition. Also, TE rarely
ulcerates. BCC conversely is usually not associated with formation
of horn cysts and papillary mesenchymal bodies. However
histological distinction is predominantly based on the higher
degree of follicular differentiation as found in TE. [6] Differen-
tiation between these two HF derived tumours is important
because of their distinct biologic behaviour and therapeutic
approach. Decreased oxygen levels are a common feature in
many tumours [7], including cutaneous squamous cell carcinoma
and melanoma. [8] While the human dermis is well-oxygenated
and the epidermis is modestly hypoxic, the HF is considered as a
moderately to severely hypoxic microenvironment. [9] A primary
mediator of hypoxia-induced gene expression in human HFs is the
hypoxia-inducible transcription factor 1 (HIF1). [10] HIF1 is
activated in several tumour types, [11] and is mainly negatively
regulated by prolyl hydroxylase 2 (PHD2); the key oxygen sensor.
[12] In hypoxic conditions, HIF1a regulates the expression of
important proteins including vascular endothelial growth factor
(VEGF-A), glucose transporter 1 (GLUT1), catalytic enzymes such
as carbonic anhydrase IX (CAIX) and pro-apoptotic BCL-2/
adenovirus E1B 19 kDa-interacting protein 3 (BNIP3). VEGF-A is
suggested as a key driver in the angiogenic response and is
overexpressed in most solid cancer. As a consequence, inhibition
of VEGF-A can suppress tumour growth. [13] GLUT1 is
responsible for glucose uptake and the expression of GLUT1
increases under hypoxic conditions inducing glycolysis. [14]
Tumours generally have high rates of glycolysis (the Warburg
effect). [15] CAIX is involved in several regulatory process that are
beneficial for tumour survival, the most important is pH
regulation. Aggressive tumour behaviour and poor patient
Figure 1. Simplified depiction of pathways affected by hypoxia. Under hypoxic conditions the expression of prolyl hydroxylase domain
proteins (PHDs) is reduced leading to an induction of hypoxia inducible factor 1a (HIF1a) expression, which becomes stable and active as a
transcription factor, together with hypoxia inducible factor 1b (HIF1b). HIF1 activation regulates the expression of several target genes whose
products address the needs of oxygen starved cells, such as vascular endothelial growth factor (VEGF-A), BCL-2/adenovirus E1B 19 kDa-interacting
protein 3 (BNIP3), glucose transporter 1 (GLUT1) and glycolytic enzymes such as carbonic anhydrase IX (CAIX). Hypoxia also influences mechanistic/
mammalian target of rapamycin complex 1 (mTORC1) signalling mainly mediated through hypoxic activation of the TSC1-TSC2 complex by REDD1.
First, phosphatidylinositol 3 kinase (PI(3)K) and protein kinase B (AKT) have been implicated in the activation of the mTOR protein kinase. One critical
target of AKT that regulates mTOR is the tumour suppressor protein, tuberin (TSC2). Tuberin negatively regulates mTOR signalling, and AKT activation
circumvents this inhibition. Constitutive mTOR signalling positively stimulates S6 kinase (S6K), a downstream effector of mTOR pathway, which
mainly drives cell growth and proliferation. Also, mTOR enhances the protein levels of HIF and consequently enhances the expression of HIF target
genes. Second, under conditions of hypoxia, intracellular ATP levels drop and AMP levels rise. AMP directly binds to a subunit of AMP activated
protein kinase (AMPK), which is then phosphorylated by serine/threonine protein kinase 11 (STK11/LKB1). Elevated concentrations of AMPK can cause
a complete inhibition of mTOR (mTORC1) activity without affecting PI(3)K-AKT signalling.
doi:10.1371/journal.pone.0106427.g001
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outcome is associated with high CAIX expression levels. [16] Also
BNIP3 is associated with poor prognosis in some cancers,
promoting apoptosis and even autophagy. [17] Hence, all of
these genes play critical roles in tumour growth. [18] Of note, they
can also be induced by mechanistic/mammalian target of
rapamycin (mTORC1) signalling [19] which is activated in
several tumour types. [20] Also, mTORC1 enhances the protein
levels of HIF via HIF1a and consequently enhances the expression
of HIF target genes. [21] Dodd et al additionally showed that
mTORC1 mediates VEGF-A expression via both HIF1a depen-
dent and independent mechanisms. [19] Conversely, hypoxia
promotes tuberous sclerosis complex 2 (TSC2) via ‘regulated in
development and DNA damage responses 19 (REDD1) that leads
to inhibition of mTORC1 and reveals a feedback mechanism
where HIF can turn off mTOR complex 1 (mTORC1). [22]
mTOR, as part of mTORC1, plays an integral role in the
coordination of cell growth and division in response to growth
factors, nutrients and the energy status of the cell (Figure 1.)). [22]
[23] Human tumours are characterised by an heterogeneous
microenvironment that differs from normal tissue with respect to
nutrient supply, pH and oxygenation. As discussed, deficiencies in
oxygenation (hypoxia) is strongly associated with tumour devel-
opment, growth, metastasis and poor response to therapy. HIF
and mTORC1 signalling are crucial in here, either directly or
indirectly acting on the hypoxia response. [23]
Based on the hypoxia affecting the HF and the known role of
both HIF and mTORC1 in tumour growth, we have previously
hypothesized that hypoxia response pathways are involved in the
pathogenesis of HF tumours. [10] If HIF and mTORC1 pathways
Table 1. Antibodies used for immunohistochemical analysis.
Antibody Dilution Producer
BNIP3 1:800 Sigma Aldrich, St. Louis, U.S.A.
CAIX 1:1000 Novus Biologicals, Littleton, U.S.A.
GLUT1 1:200 Thermo Scientific, Landsmeer, the Netherlands
HIF1a 1:50 BD Transduction Laboratories, Breda, the Netherlands
pAKT 1:25 Cell Signaling technology, Beverly, MA, U.S.A.
pS6 1:50 Cell Signaling technology, Beverly, MA, U.S.A.
pMTOR2448 1:50 Cell Signaling technology, Beverly, MA, U.S.A.
PHD2 1:250 Novus Biologicals, Littleton, US
VEGF-A 1:200 Thermo Scientific, Landsmeer, the Netherlands
BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3), carbonic anhydrase IX (CAIX), glucose transporter member 1 (GLUT1), hypoxia-inducible factor 1-
alpha (HIF1a), phosphorylated -protein kinase B (pAKT), phosphorylated-S6 (pS6), phosphorylated-mechanistic target of Rapamycin (pMTOR), prolyl hydroxylase domain
protein 2 (PHD2), vascular endothelial growth factor (VEGF-A).
doi:10.1371/journal.pone.0106427.t001
Table 2. Tumour characteristics.
Trichoepithelioma Basal cell carcinoma
Number tumours 35 45
Biopsy/excision* 19/16 (54.3/45.7) 0/45 (0.0/100.0)
Gender (m/f)* 16/21 (43.2/56.8) 24/21 (53.3/46.7)
Mean patient age in years 58.8 68.6
Tumour localisation*
Head 28 (80.0) 18 (40.0)
Nek 3 (8.6) 4 (8.9)
Trunk 3 (8.6) 15 (33.3)
Arm 0.0 (0.0) 2 (4.4)
Leg 1 (2.9) 6 (13.3)
TE Subtype*
Classic TE 35 (100.0)
Desmoplastic TE 0 (0.0)
BCC Subtype*
Superficial BCC 14 (31.1)
Nodular BCC 24 (53.3)
Infiltrative BCC 7 (15.6)
*Date are presented as n (%).
doi:10.1371/journal.pone.0106427.t002
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do contribute to the growth of HF tumours, new opportunities for
targeted therapy and diagnostics could emerge.
Therefore, we decided to examine BCC as this is the most
prevalent HF tumour and included the very similar TE. [9,10,24]
We analysed the expression of the most important target genes in
the hypoxia response using immunohistochemical stains of both
BCC and TE. To the best of our knowledge, this is the first large
series of BCC and TE to date to be analysed for HIF1 and
mTORC1 activity. Our results suggest that HIF1/mTORC1
mediated signalling is active in both tumour types.
Materials and Methods
Tissue samples
Collection, storage and use of all tissues and patient data were
performed in agreement with the "Code for Proper Secondary Use
of Human Tissue in the Netherlands". We randomly selected 45
BCC and 80 TE haematoxylin-eosin stain (HE) slides from the
Pathologic Anatomical National Automated Archive of the
Department of Pathology in the Maastricht University Medical
Centre (MUMC). A combination of search terms was used to
retrieve reports of the specific histological diagnosis. Based on the
morphological classification by Rippey, BCC were subcategorised
into superficial, nodular and infiltrative during routine histological
diagnostic examination. [2] All TE HE slides were reviewed by
three independent investigators (i.e. a dermato-pathologist (AM), a
general pathologist (BL) and a dermatologist (MT)), because the
histopathologic diagnosis of TE can present considerably more
difficulties than that of BCC. The 80 slides were reviewed based
on the presence or absence of the following characteristics:
tumour-stroma cleft formation, ulceration, epithelial primitive
structures, small keratinous cysts, inflammatory response, mitosis,
necrotic tumour cells, papillary mesenchymal bodies, stromal
oedema and peritumoral mucin production. [5] Eventually, 35 TE
were found to unambiguously fit the criteria for classic TE and
these were used for the analysis, together with 45 BCC. All of the
used samples and corresponding data were de-linked and
anonymised. Usage of tissue samples was approved by the
Maastricht Pathology Tissue Collection (MPTC) scientific com-
mittee (MPTC 2009-05).
Figure 2. Immunohistochemical stains for hypoxia inducible factor 1a (HIF1a), phosphorylated mechanistic/mammalian target of
rapamycin (pmTOR) and their target genes in basal cell carcinoma (BCC). BCL-2/adenovirus E1B 19 kDa-interacting protein 3 (BNIP3) (a);
carbonic anhydrase IX (CAIX) (b); glucose transporter 1 (GLUT1) (c); HIF1a (d); phosphorylated protein kinase B (pAKT) (e);phosphorylated ribosomal
protein S6 (pS6) (f); pmTOR (g); prolyl hydroxylase domain protein 2 (PHD2) (h); vascular endothelial growth factor (VEGF-A) (i). Original
magnification: (a–i) x 200.
doi:10.1371/journal.pone.0106427.g002
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Immunohistochemistry
Formalin fixed and paraffin embedded (FFPE) biopsies as well
as excision specimens were used. Four-micrometre sections were
cut and stained with primary antibodies, listed in table 1. Hif1a,
CAIX, Glut-1 and VEGF-A stains were performed on a Dako
autostainer system with use of a pre-treatment module using
EnVision FLEX Target Retrieval Solution, High pH (Dako,
Heverlee, Belgium). The antibodies were applied for 20 minutes at
room temperature. For HIF1a, the slides were additionally
incubated with Envision Flex Mouse Linker to amplify the signal.
The Dako Envision Flex kit (K8002) was used for secondary
detection.
For BNIP3, PHD2, pS6, pMTOR2448 and pAKT, slides were
deparaffinised in xylene, rehydrated and incubated in 0?3%
(PHD2, pMTOR2448) or 3% (BNIP3, pS6) hydrogen peroxide
(H2O2) in methanol for 30 minutes to inactivate endogenous
peroxidase activity. Antigen retrieval was performed by microwave
treatment at 90 W for 10 minutes in 10 mM citrate buffer (pH 6)
and non-specific protein binding was blocked using 3% bovine-
serum-albumin (BSA). The sections were incubated for 1 hour at
room temperature (BNIP3, PHD2) or overnight at 4uC (pS6,
pMTOR2448, pAKT). For secondary detection an Envision
detection system was used and bound antibody was visualized by
using 3,3-diaminobenzidine (DAB) for 10 minutes. After second-
ary detection, all sections were counterstained with Gill II
haematoxylin, dehydrated and coverslipped. In all reactions,
appropriate positive and negative controls were included and
always showed the expected positive resp. negative results.
Interpretation of the stains
A trained medical student of the Department of Dermatology,
MUMC (CW) and an experienced resident of the Department of
Pathology, MUMC (JE) examined all sections. Both were blinded
for patient details. Any discrepancy between the observers was
Figure 3. Percentage of positive specimens between basal cell carcinoma and trichoepithelioma. Panel a represents all tissue samples
being either positive or negative. In panel b the same results are shown, however here a cut off value of 80% of the tumour cells being positive was
used. * (P,0?05), basal cell carcinoma (BCC); trichoepithelioma (TE).
doi:10.1371/journal.pone.0106427.g003
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discussed and resolved by consensus. For all tumours, at least four
randomly chosen high-power fields (magnification 200x) per slide
were assessed to determine the percentage positive tumour cells.
The percentage of cell staining was scored as 0 (no staining), 1 (,
30% staining), 2 (30–80% staining) and 3 (.80% staining)[25].
For all assessments, the HF was used as internal standard and
considered as 100% positive.
Statistical analysis
Statistical analyses were carried out using SPSS version 20.0
software (SPSS, Chicago, IL, USA). Descriptive data were
presented as absolute numbers and percentages for categorical
data and as means with standard deviations for continuous data.
The Chi-square test for independent proportions was performed to
evaluate the differences and similarities in expression of CAIX,
BNIP3, GLUT1, HIF1a, pAKT, PHD2, pMTORC1, pS6 and
VEGF-A between BCC and TE specimens. Correlations among
the different stainings were assessed by Spearman’s correlation
coefficient. P,0?05 was considered to be statistically significant.
Results
Sample characteristics
Forty-five BCC (superficial n = 14, nodular n = 24, and infiltra-
tive n = 7) were included. Among the 80 TE cases selected, 35
were unanimously found to be classic type TE. Distribution of
patient and tumour characteristics within the TE and BCC group
are equal and listed in table 2.
Hypoxia target staining patterns in basal cell carcinoma
and trichoepithelioma
We investigated the activation status of hypoxia and mTORC1
signalling cascades by immunohistochemical analysis of BCC and
TE. Immunohistochemical staining of BNIP3, GLUT1, CAIX,
VEGF-A and PHD2 was observed in the suprabasal portion of the
overlying epidermis of the BCC and TE tumour islands and in the
internal control, the HF. Immunohistochemical staining for
HIF1a was negative in epidermis overlying the tumour islands,
while the HF showed weak scattered positive nuclear expression.
VEGF-A showed expression in the endothelial cells of blood
vessels. An overview of all stains is presented in figure 2 and 3.
Figure 4. Immunohistochemical staining for hypoxia inducible factor 1a (HIF1a) and phosphorylated mechanistic/mammalian
target of rapamycin (pmTOR) and their target genes in trichoepithelioma (TE). BCL-2/adenovirus E1B 19 kDa-interacting protein 3 (BNIP3)
(a); carbonic anhydrase IX (CAIX) (b); glucose transporter 1 (GLUT1) (c); HIF1a (d); phosphorylated protein kinase B (pAKT) (e); phosphorylated
ribosomal protein S6 (pS6) (f); p-mTOR (g); prolyl hydroxylase domain protein 2 (PHD2) (h); vascular endothelial growth factor (VEGF-A)(i). Original
magnification: (a–i) x 200.
doi:10.1371/journal.pone.0106427.g004
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Overall, about half of all BCC and TE indicate active hypoxia
signalling, however the BCC specimens tended to have less CAIX,
GLUT1, and PHD2 expression than TEs (Fig. 4a). In TE high
expression levels (.80%) of PHD2, GLUT1 and CAIX were
observed in 53?3%, 31?0% and 34?4%, respectively (Fig. 4b).
Conversely, HIF1a was more often positive in BCC nuclei than in
TE (50?0% vs 19?4% (P,0.05)). The downstream effectors BNIP3
and VEGF-A showed no significantly different expression levels.
When examining different BCC subtypes, nodular BCC har-
boured more GLUT1 and PHD2 expression compared to
superficial and infiltrative BCC with P-values of respectively
P= 0?032 and P= 0?17. An overview of the expression in BCC
and TE is presented in table 3.
mTORC1 target staining patterns in basal cell carcinoma
and trichoepithelioma
An overview of all stains is shown in figure 2,3,4 and table 3.
pAKT and pS6 were positive in the epidermis overlying the BCC
and TE tumour islands and the HF, while immunohistochemical
expression of phosphorylated mTORC1 at Ser-2448 (pmTOR) in
the overlying epidermis was negative. The HF showed some weak
and scattered pmTOR staining. In contrast, we found pAKT to be
highly expressed in 88?9% of BCC and 87?5% in TEs (P = 0?791).
As a downstream effector of pAKT, pmTOR exhibited positive
intracytoplasmic and partly membranous expression in only
15?0% of the BCC, while 33?3% of the TE showed positive
staining (P= 0?083). pS6 showed no significant difference between
intracytoplasmic staining expression in BCC (55?0%) specimens
and TE (63?3%) specimens (P= 0?935). No differences among the
BCC subtypes could be detected.
Spearman’s correlation coefficients among HIF and
mTORC1 signaling target genes
All stains were statistically analyzed for correlation of expression
patterns revealing the following significant correlations. In BCC,
significant correlations between CAIX and GLUT1 (r = 0?369,
P= 0?024), CAIX and pS6 (r = 0?522, P = 0?001) and CAIX and
PHD2 (r = 0?426, P= 0?007) were detected as well as between
PHD2 and BNIP3 (r = 0?485, P= 0?003) and PHD2 and pS6
(r = 0?399, P= 0?012). Furthermore, the expression of VEGF-A
correlated significantly with that of pMTOR (r = 0?342,
P= 0?033). Moreover in TE, PHD2 was significantly correlated
with CAIX (r = 0?438, P= 0?017) and GLUT1 (r = 0?544,
P= 0?003). Lastly, pAKT expression correlates significantly with
pS6 (r = 0?438, P= 0?015) and VEGF-A with pMTOR (r= 0?502,
P= 0?07) in TE.
Discussion
The HIF and mTORC1 signalling pathways play crucial roles
in many malignancies. [23] To the best of our knowledge, we are
the first to perform a systematic analysis of HIF and mTORC1
signalling in both BCC and TE. Although TE showed significantly
more expression of CAIX, Glut1 and PHD2, this was only in the
proportion of samples with high expression levels of at least 80%
and thus not likely to reflect a genuine difference between the two
tumour types. The correlations found between components of HIF
signalling and the mTORC1 pathway are in line with known
crosstalk between both pathways.[23] GLUT1, CAIX and BNIP3
are the most important readouts for HIF1a signalling [26–28] and
our data show positivity of all three target genes in the majority of
both BCC and TE. Positive VEGF-A staining patterns were found
in the endothelial cells of blood vessels as well as in BCC/TE
tumour cells. However, VEGF-A expression was not specifically
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tumour related, since some weak staining was also noted in the
basal cell layer of epidermis adjacent to the tumours. These low
and weak VEGF-A expression levels are in agreement with earlier
studies in BCC and other benign and malignant skin tumours
[29,30] and might be explained by the low levels of mTORC1
expression found (see below), since recent evidence indicates that
mTORC1 can drive VEGF-A expression. [19] It also fits with the
low metastatic behaviour of BCC [29]. Accordingly, strong
VEGF-A expression is observed in the more aggressive and
potentially metastasizing squamous cell carcinoma and melanoma.
[29,31]
Furthermore, we found expression of PHD2 in 63?3% of TE
and 43?9% of BCC specimens, whereas expression of HIF1a itself
was low or even undetectable. Several in vitro studies have shown
that PHD2 is transiently upregulated in a HIF-dependent manner
under normoxic as well as mild hypoxic conditions, which could
suggest that HIF might induce an autoinhibitory effect on its own
activity. [32] Moreover, D’Angelo et al demonstrated that hypoxic
upregulation of PHD2 acts as a feedback mechanism to stop
hypoxic signalling in reoxygenated cells. [33] Hence, we postulate
that the lack of HIF1a in BCC and TE specimens can be
explained by the presence of PHD2.
Activity of the mTORC1 pathway was assessed by use of the
upstream regulator pAKT and downstream target pS6. pAKT
was positive in 88?9% of BCC and 87?5% of TE, while 55% of
BCC and 61?3% of TE specimens were positive for pS6,
supporting the presence of active mTOR signalling. The positive
stains for pAKT and pS6 found in our study are consistent with
the known activity of PI(3)K/AKT signalling in BCC. [34] In
addition, strong expression of pAKT and pS6 has been observed
in a variety of skin neoplasms including Bowen’s disease,
keratoacanthoma, squamous cell carcinoma and extramammary
Paget’s disease. [35,36] However, despite positive staining of
pAKT and pS6, hardly any mTORC1 phosphorylation at Ser-
2448 was detected in both tumour types. This observation is
consistent with two other studies reporting weak positivity of
mTOR (Ser-2448) in only 7?7% of BCC [37] and 36% positivity
among 85 epidermal tumours other than BCC. [36] Ser-2448 is
the mTORC1phosphorylation site modified either directly by
AKT or by the downstream target of mTORC1, p70S6 kinase,
making it the most important marker for activation of mTOR.
[38] However, the upregulation of up- and downstream target
genes of the mTORC1 signalling cascade do suggest activation of
downstream mTORC1 signalling components downstream, which
could be attributed to PI(3)K- signalling. [39] In addition, it is
known that multiple feedback loops exist, for example S6 kinase
can dampen growth factor receptor signalling to PI3K. [40]
Overall the immunohistochemical analysis is consistent with
activity of HIF1 and mTORC1 signalling in both BCC and TE, in
addition to the known PI(3)K-AKT activity in BCC. [34] We also
showed that the number of HIF1a positive cells was significantly
higher in BCC than in TE, which might be explained by the fact
that BCC tumour nests are generally larger than the TE tumour
nests and consequently could be more hypoxic. Nodular BCC tend
to have more GLUT1 and PHD2 expression when compared to
superficial and infiltrative BCC, which could similarly be due to
them being more hypoxic.
Advanced insights in molecular pathways active in cancer
development have already resulted in the development of novel
topical and systemic targeted therapies as a rational approach to
the management of many (skin) cancers. [41] Our results suggest
that it might be of interest to further explore the contribution of
HIF1 and mTORC1 signalling to BCC and TE growth. Deeper
insights into such signalling pathways might eventually result in the
identification of novel targets for treatment. Finally a better
understanding of alterations in gene expression could be used to
develop better histological diagnostics, since at this moment
immunohistochemical analysis of HIF, mTORC1 and their target
genes does not provide a reliable diagnostic tool for the
discrimination of BCC and TE.
Acknowledgments
We are grateful to Reno Bladergroen and Roy Cloots for their technical
support.
Author Contributions
Conceived and designed the experiments: TB MVS. Performed the
experiments: TB CW JE VW MT AVM BL. Analyzed the data: TB CW
PN. Contributed reagents/materials/analysis tools: TB CW. Contributed
to the writing of the manuscript: TB CW AVM PN MVS.
References
1. Flohil SC, Seubring I, van Rossum MM, Coebergh JW, de Vries E, et al. (2013)
Trends in Basal cell carcinoma incidence rates: a 37-year Dutch observational
study. J Invest Dermatol 133: 913–918.
2. Rippey JJ (1998) Why classify basal cell carcinomas? Histopathology 32: 393–
398.
3. Youssef KK, Van Keymeulen A, Lapouge G, Beck B, Michaux C, et al. (2010)
Identification of the cell lineage at the origin of basal cell carcinoma. Nat Cell
Biol 12: 299–305.
4. Kasper M, Jaks V, Hohl D, Toftgard R (2012) Basal cell carcinoma - molecular
biology and potential new therapies. J Clin Invest 122: 455–463.
5. Arits AH, Van Marion AM, Lohman BG, Thissen MR, Steijlen PM, et al.
(2011) Differentiation between basal cell carcinoma and trichoepithelioma by
immunohistochemical staining of the androgen receptor: an overview.
Eur J Dermatol 21: 870–873.
6. Weedon D (2009) Skin Pathology. Tokyo: Churchill Livingstone.
7. Yang Y, Sun M, Wang L, Jiao B (2013) HIFs, angiogenesis, and cancer. J Cell
Biochem 114: 967–974.
8. Nys K, Maes H, Dudek AM, Agostinis P (2011) Uncovering the role of hypoxia
inducible factor-1alpha in skin carcinogenesis. Biochim Biophys Acta 1816: 1–
12.
9. Evans SM, Schrlau AE, Chalian AA, Zhang P, Koch CJ (2006) Oxygen levels in
normal and previously irradiated human skin as assessed by EF5 binding.
J Invest Dermatol 126: 2596–2606.
10. van Steensel MA, van Geel M, Badeloe S, Poblete-Gutierrez P, Frank J (2009)
Molecular pathways involved in hair follicle tumor formation: all about
mammalian target of rapamycin? Exp Dermatol 18: 185–191.
11. Ruan K, Song G, Ouyang G (2009) Role of hypoxia in the hallmarks of human
cancer. J Cell Biochem 107: 1053–1062.
12. Chan DA, Giaccia AJ (2010) PHD2 in tumour angiogenesis. Br J Cancer 103:
1–5.
13. Vasudev NS, Reynolds AR (2014) Anti-angiogenic therapy for cancer: current
progress, unresolved questions and future directions. Angiogenesis 17: 471–494.
14. Sadlecki P, Bodnar M, Grabiec M, Marszalek A, Walentowicz P, et al. (2014)
The role of Hypoxia-inducible factor-1 alpha, glucose transporter-1, (GLUT-1)
and carbon anhydrase IX in endometrial cancer patients. Biomed Res Int 2014:
616850.
15. Warburg O (1956) On the origin of cancer cells. Science 123: 309–314.
16. Sedlakova O, Svastova E, Takacova M, Kopacek J, Pastorek J, et al. (2014)
Carbonic anhydrase IX, a hypoxia-induced catalytic component of the pH
regulating machinery in tumors. Front Physiol 4: 400.
17. Chinnadurai G, Vijayalingam S, Gibson SB (2008) BNIP3 subfamily BH3-only
proteins: mitochondrial stress sensors in normal and pathological functions.
Oncogene 27 Suppl 1: S114–127.
18. Semenza GL (2010) Defining the role of hypoxia-inducible factor 1 in cancer
biology and therapeutics. Oncogene 29: 625–634.
19. Dodd KM, Yang J, Shen MH, Sampson JR, Tee AR (2014) mTORC1 drives
HIF-1alpha and VEGF-A signalling via multiple mechanisms involving 4E-BP1,
S6K1 and STAT3. Oncogene.
20. Arsham AM, Howell JJ, Simon MC (2003) A novel hypoxia-inducible factor-
independent hypoxic response regulating mammalian target of rapamycin and
its targets. J Biol Chem 278: 29655–29660.
mTOR and Hypoxia Signalling in BCC and Trichoepithelioma
PLOS ONE | www.plosone.org 9 September 2014 | Volume 9 | Issue 9 | e106427
21. Duvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, et al. (2010) Activation of
a metabolic gene regulatory network downstream of mTOR complex 1. Mol
Cell 39: 171–183.
22. Brugarolas J, Lei K, Hurley RL, Manning BD, Reiling JH, et al. (2004)
Regulation of mTOR function in response to hypoxia by REDD1 and the
TSC1/TSC2 tumor suppressor complex. Genes Dev 18: 2893–2904.
23. Wouters BG, Koritzinsky M (2008) Hypoxia signalling through mTOR and the
unfolded protein response in cancer. Nat Rev Cancer 8: 851–864.
24. Rathman-Josserand M, Genty G, Lecardonnel J, Chabane S, Cousson A, et al.
(2013) Human Hair Follicle Stem/Progenitor Cells Express Hypoxia Markers.
J Invest Dermatol.
25. Krahl D, Sellheyer K (2010) p75 Neurotrophin receptor differentiates between
morphoeic basal cell carcinoma and desmoplastic trichoepithelioma: insights
into the histogenesis of adnexal tumours based on embryology and hair follicle
biology. Br J Dermatol 163: 138–145.
26. Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, et al. (2000)
Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer
Res 60: 7075–7083.
27. Nakayama K (2009) Cellular signal transduction of the hypoxia response.
J Biochem 146: 757–765.
28. Zhang HM, Cheung P, Yanagawa B, McManus BM, Yang DC (2003) BNips: a
group of pro-apoptotic proteins in the Bcl-2 family. Apoptosis 8: 229–236.
29. Bowden J, Brennan PA, Umar T, Cronin A (2002) Expression of vascular
endothelial growth factor in basal cell carcinoma and cutaneous squamous cell
carcinoma of the head and neck. J Cutan Pathol 29: 585–589.
30. Weninger W, Uthman A, Pammer J, Pichler A, Ballaun C, et al. (1996) Vascular
endothelial growth factor production in normal epidermis and in benign and
malignant epithelial skin tumors. Lab Invest 75: 647–657.
31. Toth-Jakatics R, Jimi S, Takebayashi S, Kawamoto N (2000) Cutaneous
malignant melanoma: correlation between neovascularization and peritumor
accumulation of mast cells overexpressing vascular endothelial growth factor.
Hum Pathol 31: 955–960.
32. Jokilehto T, Rantanen K, Luukkaa M, Heikkinen P, Grenman R, et al. (2006)
Overexpression and nuclear translocation of hypoxia-inducible factor prolyl
hydroxylase PHD2 in head and neck squamous cell carcinoma is associated with
tumor aggressiveness. Clin Cancer Res 12: 1080–1087.
33. D’Angelo G, Duplan E, Boyer N, Vigne P, Frelin C (2003) Hypoxia up-regulates
prolyl hydroxylase activity: a feedback mechanism that limits HIF-1 responses
during reoxygenation. J Biol Chem 278: 38183–38187.
34. Jee SH, Chiu HC, Tsai TF, Tsai WL, Liao YH, et al. (2002) The phosphotidyl
inositol 3-kinase/Akt signal pathway is involved in interleukin-6-mediated Mcl-1
upregulation and anti-apoptosis activity in basal cell carcinoma cells. J Invest
Dermatol 119: 1121–1127.
35. Chen S, Nakahara T, Uchi H, Takeuchi S, Takahara M, et al. (2009)
Immunohistochemical analysis of the mammalian target of rapamycin signalling
pathway in extramammary Paget’s disease. Br J Dermatol 161: 357–363.
36. Chen SJ, Nakahara T, Takahara M, Kido M, Dugu L, et al. (2009) Activation of
the mammalian target of rapamycin signalling pathway in epidermal tumours
and its correlation with cyclin-dependent kinase 2. Br J Dermatol 160: 442–445.
37. Karayannopoulou G, Euvrard S, Kanitakis J (2013) Differential expression of p-
mTOR in cutaneous basal and squamous cell carcinomas likely explains their
different response to mTOR inhibitors in organ-transplant recipients. Antican-
cer Res 33: 3711–3714.
38. Chiang GG, Abraham RT (2005) Phosphorylation of mammalian target of
rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. J Biol Chem 280:
25485–25490.
39. Hardie DG (2005) New roles for the LKB1—.AMPK pathway. Curr Opin Cell
Biol 17: 167–173.
40. Fruman DA, Rommel C (2014) PI3K and cancer: lessons, challenges and
opportunities. Nat Rev Drug Discov 13: 140–156.
41. Liu LS, Colegio OR (2013) Molecularly targeted therapies for nonmelanoma
skin cancers. Int J Dermatol 52: 654–665.
mTOR and Hypoxia Signalling in BCC and Trichoepithelioma
PLOS ONE | www.plosone.org 10 September 2014 | Volume 9 | Issue 9 | e106427
